| Literature DB >> 32953972 |
Ahmed A Aljorfi1, Abdulhameed H Alkhamis2.
Abstract
INTRODUCTION: A Loop ileostomy is one of the most common techniques used in colorectal surgery to establish a reversible faecal diversion and bypass the large bowels, in order to protect either a downstream colorectal anastomosis or a coloanal anastomosis. However, it is a procedure that can cause a plethora of complications including long term ones such as the psychological effects. Currently, there is no consensus regarding the optimal time to perform closure of a loop ileostomy. Some studies suggested the early reversal of ileostomy procedure as a solution to reduce these complications. This study aims to review the available literature in order to ascertain the benefits behind early closure of loop ileostomy.Entities:
Year: 2020 PMID: 32953972 PMCID: PMC7481925 DOI: 10.1155/2020/9876527
Source DB: PubMed Journal: Surg Res Pract ISSN: 2356-6124
Comparison between patient baseline demographics.
| Reference | Number of patients | Gender (F : M) | Age (years) | ASA | Main diagnosis | Index operation | Adjuvant radio-chemotherapy | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I | II | III | IV | |||||||||||||||||||||||||
| EC | LC | EC | LC | EC | LC | EC | LC | EC | LC | EC | LC | EC | LC | EC | LC | EC | LC | EC | LC | |||||||||
| Danielsen et al. | 55 | 57 | 56 : 44 | 37 : 63 | 67 | 67 | 22% | 33% | 38% | 23% | 33% | 35% | 5% | 2% | Rectal cancer | TME | 29% | 28% | ||||||||||
| Figueiredo et al. | 65a | 155b | 79 | 45 : 55a | 50 : 50b | 34 : 66 | 60a | 62b | 62 | 28%a | 29%b | 20% | 63%a | 63%b | 67% | 9%a | 8%b | 13% | —a | —b | — | Rectal cancer | TME | 75%a | 58%b | 59% | ||
| Wanglin et al. | 179 | 179 | 88 : 91 | 88 : 91 | 45.7 | 45.6 | 56.4%c | 56.4%c | 56.4%c | 56.4%c | 44%d | 44%d | 44%d | 44%d | Cancer (20.1%) IBD (69.8%) others (10.1%) | AC/LI (36.3%) CP/IPAA (31.3%) LAR/DLI (10.1%) TP/IPAA (6.7%) others (15.6%) | AC/LI (27.9%) CP/IPAA (30.7%) LAR/DLI (11.7%) TP/IPAA (6.7%) others (22.9%) | 17% | 17% | |||||||||
| Park et al. | 55 | 57 | 31 : 24 | 21 : 36 | 67 | 67 | n/r | n/r | n/r | n/r | n/r | n/r | n/r | n/r | Rectal cancer | TME | 69% | 68% | ||||||||||
aClosure before 60 days of stoma creation. bClosure 61–90 days after stoma creation. cPercentage of ASA I and II grouped together. dPercentage of ASA III and IV grouped together. n/r: not reported; EC: early closure; LC: late closure; TME: total mesorectal excision; CP/IPAA: complete proctectomy with ileal-pouch anal anastomosis; LAR/DLI: low anterior resection/diverting loop ileostomy; TP/IPAA: total proctocolectomy with ileal-pouch anal anastomosis; IBD: inflammatory bowel disease.
Comparison between the postoperative complications.
| Complication | Reference | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Danielsen et al. | Figueiredo et al. | Wanglin et al. | Park et al. | ||||||
| EC ( | LC ( | EC | LC ( | EC ( | LC ( | EC ( | LC ( | ||
| <60 d ( | 61–90d ( | ||||||||
| Infection | 2 | 0 | 1 | 3 | 1 | 4 | 3 |
|
|
| Parastomal hernia |
|
| 3%b | 11%b | 8%b |
|
|
|
|
| Anastomotic stenosis | 0 | 1 |
|
|
|
|
|
|
|
| Reoperation | 5a | 4a |
|
|
| 1 | 3 |
|
|
| Small bowel obstruction | 1 | 1 | 0b | 1%b | 1%b | 6 | 3 |
|
|
| Anastomotic leakage | 0 | 1 | 1 | 0 | 4 | 1 | 1 |
|
|
| Late anastomotic leakage |
|
| 1%b | 3%b | 1%b |
|
|
|
|
| Ileus |
|
| 1 | 4 | 4 | 22 | 24 |
|
|
| Electrolyte disorder |
|
| 4 | 3 | 1 |
|
|
|
|
| Abscess | 3a | 2a | 0 | 0 | 3 | 1 | 3 |
|
|
| Postop bleeding | 0 | 0 | 0 | 2 | 2 | 1 | 2 |
|
|
| Nausea/vomiting | 1 | 2 |
|
|
|
|
|
|
|
| Pain | 1 | 1 |
|
|
|
|
|
|
|
| Allergy | 0 | 0 |
|
|
|
|
|
|
|
| Pancreatitis | 0 | 0 |
|
|
|
|
|
|
|
| Liver insufficiency | 0 | 0 |
|
|
|
|
|
|
|
| Cardiopulmonary | 0 | 0 |
|
|
|
|
|
|
|
| Urinary blockage |
|
| 0 | 3 | 0 |
|
|
|
|
| Urinary infection |
|
| 0 | 1 | 1 |
|
|
|
|
| Venous thromboembolism |
|
| 0 | 0 | 1 |
|
|
|
|
n/r: not reported; EC: early closure; LC: late closure; awithin one-year follow-up; bwithin 66 months of follow-up;